Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anfoxacin
- Development stage
- Phase 2
- Lead developer
- Anhui Global Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Anfoxacin is a fluoroquinolone antibiotic developed by Anhui Global Pharmaceutical. It functions by inhibiting bacterial DNA gyrase and topoisomerase IV, which are critical enzymes for DNA replication, transcription, and repair in bacteria. The drug has been investigated in Phase 2 clinical trials in China for the treatment of pyelonephritis and respiratory tract infections, often compared against established fluoroquinolones like levofloxacin.
- Other names
- anfoxacin hydrochloride
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on anfoxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anfoxacin.